home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 11/07/19

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - ObsEva Announces Third Quarter 2019 Financial Results

– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET – &#...
OBSV - Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

   Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women...

OBSV - Correction: ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

  Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phas...

OBSV - ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

  Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phas...
OBSV - ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

  Geneva, Switzerland and Boston, MA –November 4, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s repr...

OBSV - ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

  FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for ser...

OBSV - Key events next week - healthcare

Noteworthy events during the week of October 13 - 19 for healthcare investors. More news on: Flexion Therapeutics, Inc., Johnson & Johnson, ArQule, Inc., Healthcare stocks news, , Read more ...

OBSV - ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while maintaining bone health   2019 American Conference on Pharmacometrics Quali...

OBSV - ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

Geneva, Switzerland and Boston, MA – October 9, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s rep...

OBSV - Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (...
Previous 10 Next 10